Exophytic Tumor of the Bladder (Urothelial Carcinoma)

Overview

Exophytic bladder tumor refers to a growth that projects outward from the inner lining (urothelium) into the bladder lumen. The most common histology for an exophytic bladder tumor is urothelial carcinoma (also called transitional cell carcinoma). It accounts for more than 90 % of bladder cancers in the United States and Europe.

• Who it affects: Primarily adults over 55 years; men are 3–4 times more likely than women to develop bladder cancer.
• Prevalence: According to the CDC, there are about 80,000 new cases of bladder cancer each year in the U.S., and roughly 70 % present as non‑muscle‑invasive (including exophytic) disease at diagnosis.
• Geography: Higher incidence in industrialized nations, especially in regions with high tobacco use.

When the tumor remains confined to the urothelium or lamina propria, it is classified as “non‑muscle‑invasive bladder cancer” (NMIBC). Exophytic lesions are usually detected during cystoscopy because they are visible as papillary or cauliflower‑like growths.

Symptoms

Symptoms can be subtle early on and may mimic benign urinary conditions. Any new or persistent urinary change should be evaluated.

• Hematuria (blood in urine): The most common presenting sign—often painless and may be visible (gross) or detectable only on lab testing (microscopic).
• Frequent urination: Increased urge to void, especially at night (nocturia).
• Urgency: Sudden, strong need to urinate that can be difficult to control.
• Painful urination (dysuria): Burning sensation during voiding.
• Pain in lower abdomen or pelvic region: May result from tumor irritation.
• Urinary retention: Rare, but a large exophytic mass can obstruct the bladder outlet.
• Clots in urine: Caused by larger bleeding lesions.
• Unexplained weight loss or fatigue: Usually a sign of more advanced disease.

Because bladder cancer can be asymptomatic in early stages, routine screening is only recommended for high‑risk groups (e.g., heavy smokers, occupational exposure to aromatic amines).

Causes and Risk Factors

Primary Causes

The exact trigger for urothelial carcinoma is not fully understood, but it results from cumulative DNA damage to the urothelium leading to malignant transformation.

Major Risk Factors

• Tobacco smoking: Responsible for ~50 % of cases; risk rises with pack‑years.
• Occupational exposures: Aromatic amines (e.g., in dye, rubber, leather, paint, and petroleum industries).
• Chronic bladder irritation: Long‑standing catheter use, recurrent urinary tract infections, or bladder stones.
• Arsenic‑contaminated water: Notable in certain regions of Bangladesh and Taiwan.
• Schistosoma haematobium infection: Leads to squamous cell carcinoma more than urothelial carcinoma, but still a bladder cancer risk.
• Family history/genetics: Mutations in FGFR3, TP53, and Lynch syndrome (DNA mismatch repair defects) increase susceptibility.
• Prior radiation therapy: Pelvic radiation for other malignancies raises risk.
• Age and sex: Incidence rises sharply after age 55; men have higher rates.

Diagnosis

Diagnosis combines a thorough history, physical exam, imaging, and direct visualization of the bladder.

Step‑by‑step diagnostic pathway

1. Urinalysis & urine cytology: Detects microscopic hematuria and malignant cells.
2. Imaging:
   • CT urography (preferred) – provides detailed anatomy and assesses upper urinary tract.
   • Ultrasound – useful in patients where radiation is a concern.
   • MRI – reserved for staging when CT is equivocal.
3. Cystoscopy: Gold‑standard; a thin camera inserted through the urethra visualizes the lesion. Most exophytic tumors appear as papillary, frond‑like growths.
4. Transurethral resection of bladder tumor (TURBT): During cystoscopy, the tumor is removed (or biopsied) for histopathologic analysis. This provides:
   • Grade (low vs. high)
   • Stage (whether it invades muscle)
   • Presence of carcinoma in situ (CIS)
5. Pathology & molecular testing: Determines FGFR3, HER2, PD‑L1 status, which can guide targeted therapy.

According to the American Cancer Society, accurate staging is critical because treatment differs dramatically between non‑muscle‑invasive and muscle‑invasive disease.

Treatment Options

Treatment is individualized based on tumor grade, stage, patient health, and preferences.

Non‑Muscle‑Invasive (exophytic) disease

• Transurethral resection of bladder tumor (TURBT): Primary curative approach; removes visible tumor.
• Intravesical therapy:
  • Immediate postoperative chemotherapy (e.g., mitomycin C, gemcitabine) to eradicate residual cells.
  • Intravesical BCG (Bacillus Calmette‑Guérin): Immunotherapy given weekly for 6 weeks, then maintenance; reduces recurrence in high‑grade tumors.
  • Intravesical chemotherapeutic agents: Docetaxel, valrubicin for BCG‑unresponsive disease.
• Maintenance surveillance: Cystoscopy every 3‑6 months for the first 2 years, then annually if stable.

Muscle‑Invasive or Recurrent disease

• Radical cystectomy: Removal of the bladder, surrounding tissue, and pelvic lymph nodes. Recommended for T2 or higher disease.
• Bladder‑preserving trimodality therapy: Maximal TURBT + concurrent chemoradiation (often cisplatin‑based) + maintenance intravesical therapy.
• Systemic chemotherapy: Platinum‑based regimens (e.g., MVAC—methotrexate, vinblastine, doxorubicin, cisplatin) for metastatic or neoadjuvant settings.
• Targeted therapy & immunotherapy:
  • FGFR inhibitors (erdafitinib) for FGFR3‑mutated tumors.
  • PD‑1/PD‑L1 inhibitors (pembrolizumab, atezolizumab) for cisplatin‑ineligible or advanced disease.

Lifestyle & supportive measures

• Smoking cessation – the single most impactful change.
• Hydration: Aim for ≥2 L of fluid daily unless contraindicated.
• Nutrition: Emphasize fruits, vegetables, and lean protein; limit processed meats.
• Physical activity: 150 min/week of moderate aerobic exercise improves overall outcomes.

Living with Exophytic Tumor of the Bladder (Urothelial Carcinoma)

Managing a bladder cancer diagnosis involves medical follow‑up, self‑care, and emotional support.

Daily Management Tips

• Hydrate regularly to dilute urine and facilitate early detection of hematuria.
• Maintain a voiding diary: Record frequency, volume, and any blood; share with your urologist.
• Adhere to intravesical treatment schedules: Missing doses can increase recurrence risk.
• Pelvic floor exercises (Kegels): May improve bladder control after surgery.
• Skin care for catheter or stoma sites: Keep clean, use barrier creams, and monitor for infection.
• Psychosocial support: Join bladder cancer support groups (e.g., Bladder Cancer Advocacy Network) and consider counseling.
• Medication review: Discuss all drugs with your provider; avoid NSAIDs if you have bleeding risk.

Follow‑up Schedule (Typical)

Time after Treatment	Recommended Tests
3‑6 months	Cystoscopy + urine cytology
Every 6 months (Years 1‑2)	Cystoscopy, imaging if indicated
Annually (Years 3‑5)	Cystoscopy, urine cytology
Beyond 5 years	Individualized; most recurrences happen early

Prevention

While not all bladder cancers are preventable, risk can be markedly lowered.

• Quit smoking: Reduces risk by up to 50 % within 10 years of cessation.
• Occupational safety: Use protective equipment and follow safety protocols when handling aromatic amines.
• Drink clean water: Avoid arsenic‑contaminated sources; use filtration if needed.
• Limit exposure to certain medications: Long‑term cyclophosphamide can increase risk; discuss alternatives with your oncologist.
• Maintain a healthy diet: Diets rich in fruits, vegetables, and antioxidants are associated with lower bladder cancer incidence (NIH).
• Regular medical check‑ups: High‑risk individuals should undergo annual urinalysis and, if indicated, imaging.

Complications

If left untreated or if disease progresses, several serious complications can arise.

• Progression to muscle‑invasive disease: Increases need for radical surgery and lowers survival.
• Upper urinary tract involvement: Tumor spread to ureters or kidneys, causing obstruction and renal failure.
• Hematuria leading to anemia: Chronic blood loss may require transfusion.
• Urinary obstruction: Large tumors can block the bladder outlet or ureters.
• Metastasis: Common sites include lymph nodes, liver, lungs, and bone.
• Treatment‑related adverse effects: BCG cystitis, chemotherapy toxicity, surgical complications (e.g., ileus, infection).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, American Cancer Society, National Cancer Institute, WHO, Cleveland Clinic, European Urology Journal, JAMA Oncology. All URLs accessed June 2026.